Although direct pharmacological targeting of mutated RAS has not led to widespread clinical therapies at this time, Downward et al. suggested that mutant KRAS rendered tumor cells more susceptible to proteasome inhibitors.38 This evidence concerns the gene KRAS and neoplasm.